ClinicalTrials.gg

Program

IBI112

A development code. Also written as “Period 2 IBI112 dose 3”, “Period 1 IBI112 dose 1” and “Period 1 IBI112 dose 2”.

Its studies are mostly in Psoriasis · Colitis, Ulcerative, led by Innovent Biologics.

Furthest: phase 3, since Dec 1, 20226 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics61 open or runningphase 3since Dec 1, 2022Aug 3, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2020First study: phase 1 study in Healthy SubjectsFirst studyNCT04511624 · 46 enrolled · China
  2. Aug 5, 2021Phase 2 study in PsoriasisNCT05003531 · 250 enrolled · China
  3. May 6, 2022Phase 2 study in Colitis, UlcerativeNCT05377580 · 150 enrolled · China
  4. Dec 1, 2022Phase 3 study in PsoriasisNCT05645627 · 500 enrolled · China
  5. Sep 13, 2023Phase 3 study in PsoriasisNCT06049810 · 566 enrolled · China
  6. Nov 24, 2025Phase 3 study in PsoriasisNCT07265284 · 104 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07265284Psoriasis · China3RecruitingSep 30, 2026104
NCT06049810Psoriasis · China3CompletedApr 29, 2025566
NCT05645627Psoriasis · China3CompletedAug 9, 2023500
NCT05377580Colitis, Ulcerative · China2CompletedJun 21, 2024150
NCT05003531Psoriasis · China2CompletedMar 25, 2022250
NCT04511624Healthy Subjects · China1CompletedJul 22, 202246

How it is read

Names in the registry

  • “IBI112”, 7 entries
  • “Period 2 IBI112 dose 3”, 1 entry
  • “Period 1 IBI112 dose 1”, 1 entry
  • “Period 1 IBI112 dose 2”, 1 entry
  • “Period 2 IBI112 dose 4”, 1 entry

Codes read as this program: IBI112.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.